• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

    22.71 -0.49 (-2.11%)
    Streaming Delayed Price Updated: 11:08 AM EST, Jan 13, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Apellis Pharmaceuticals, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    19 20 Next >
    News headline image
    Roblox, Carvana, eBay, C.H. Robinson Worldwide, Huntington Ingalls Industries And Other Big Stocks Moving Higher On Thursday ↗
     
    Via Benzinga
    News headline image
    APELLIS PHARMACEUTICALS INC (NASDAQ:APLS) Reports Mixed Q2 2025 Results with EPS Beat and Revenue Miss ↗
    Apellis Pharmaceuticals (APLS) reported mixed Q2 2025 results, missing revenue estimates ($178.49M vs. $192.29M) but beating EPS (-$0.33 vs. -$0.49). Shares rose 4.58% pre-market as FDA approval for... 
    Via Chartmill
    News headline image
    Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For July 31, 2025 ↗
     
    Via Benzinga
    News headline image
    Earnings Scheduled For May 7, 2025 ↗
     
    Via Benzinga
    News headline image
    Apellis Pharmaceuticals's Earnings Outlook ↗
     
    Via Benzinga
    News headline image
    Breaking Down Apellis Pharmaceuticals: 6 Analysts Share Their Views ↗
     
    Via Benzinga
    News headline image
    FDA Approval For Empaveli Marks Key Milestone In Apellis' Rare Disease Portfolio ↗
    FDA approves Apellis' Empaveli for rare kidney diseases, with trial data showing strong efficacy in reducing proteinuria and clearing C3 deposits. 
    Via Benzinga
    News headline image
    Why Retail Investors Are Turning Sharply Bullish On Apellis Pharmaceuticals ↗
    The FDA approved Apellis’ drug Empaveli for two rare kidney diseases, following strong results from a Phase 3 trial. 
    Via Stocktwits
    News headline image
    FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Apellis Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (15 Ratings) ↗
     
    Via Benzinga
    News headline image
    Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    What 13 Analyst Ratings Have To Say About Apellis Pharmaceuticals ↗
     
    Via Benzinga
    News headline image
    Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN
    From Apellis Pharmaceuticals, Inc.; Sobi
    Via GlobeNewswire
    News headline image
    Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 17 Analysts ↗
     
    Via Benzinga
    News headline image
    Why Apellis Pharmaceuticals Wilted on Wednesday ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Sarepta Therapeutics, Mercury Systems, Arista Networks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    What 9 Analyst Ratings Have To Say About Apellis Pharmaceuticals ↗
     
    Via Benzinga
    News headline image
    Apellis Announces Craig Wheeler to Join the Board of Directors
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals ↗
    Apellis' Empaveli receives FDA Priority Review for rare kidney diseases C3G and IC-MPGN. Phase 3 data show strong efficacy in proteinuria reduction. 
    Via Benzinga
    News headline image
    Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    JP Morgan Cut Apellis' Price Forecasts, Cites Longer Peak Sales Timing For Syfovre ↗
    JP Morgan sees steady growth for Apellis' Syfovre, lowering the price target to $45. Syfovre sales hit $167.8M in Q4, with over 94,000 doses delivered. 
    Via Benzinga
    News headline image
    Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst ↗
    JP Morgan sees Apellis' Syfovre as a potential $1.5B drug. Empaveli's approval for C3G/IC-MPGN could drive stock growth with a U.S. launch in 2H 2025. 
    Via Benzinga
    News headline image
    Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    19 20 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.